03 Jun 2020 --- A DSM probiotic is the latest strain to be investigated in the fight against COVID-19. Duke University Health System’s Institutional Review Board has approved a clinical trial of Lactobacillus rhamnosus GG, which is part of the Culturelle brand from DSM’s i-Health, Inc. The probiotic will be trialed in households exposed to COVID-19, with the researchers anticipating that it may be able to directly reduce the risk of SARS-CoV-2 infection and severity of COVID-19 disease and symptoms in household contacts and caregivers of known coronavirus patients.
